TABLE 4.
mRNA expression changes from pretreatment to week 1 of therapy in slow and fast respondersa
| Analyte | Fast responders
|
Slow responders
|
||||
|---|---|---|---|---|---|---|
| Mean FR/SR expression factor (fold) | SE | P | Mean FR/SR expression factor (fold) | SE | P | |
| IL-4*b | 7.68 | 1.5-36.96 | 0.018 | 2 | 0.37-11.16 | 0.3 |
| IL-4 | 0.71 | 0.11-7.13 | 0.69 | 0.06 | 0.26-0.98 | 0.002 |
| IL-4δ2 | 18.93 | 0.6-488.3 | 0.02 | 47.32 | 4.01-703.4 | 0.0001 |
| TGF-β | 2 | 0.091-22.5 | 0.4 | 0.94 | 0.12-6.61 | 0.74 |
| TGF-βRII | 2.25 | 0.17-43.41 | 0.39 | 1.1 | 0.087-14.4 | 0.71 |
| Foxp3 | 5.03 | 0.51-43.98 | 0.11 | 1.95 | 0.25-21.1 | 0.34 |
| GATA-3 | 3.61 | 0.34-29.18 | 0.13 | 1.5 | 0.18-13.4 | 0.42 |
| T-bet | 2.564 | 0.225-43.214 | 0.320 | 1.237 | 0.080-16.828 | 0.591 |
| IFN-γ | 1.875 | 0.375-10.708 | 0.472 | 2.163 | 0.293-12.832 | 0.257 |
a
Changes in mRNA expression from pretreatment to week 1 of therapy are shown for fast and slow responders. The factors represent the level of transcript expression at week 1 compared to that at the pretreatment time point. Values above 1 indicate upregulation and values below 1 downregulation. FR, fast responder; SR, slow responder. Statistically significant P values are shown in bold.
b
The primers used amplified both IL-4 and IL-4δ2.